Is MADRIGAL PHARMACEUTICALS, INC. (MDGL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 9.4% / 30% | 0.5% / 30% | N/A | ✓ HALAL |
| DJIM | 1.2% / 33% | 9.4% / 33% | 0.5% / 33% | N/A | ✓ HALAL |
| MSCI | 11.5% / 33% | 88.9% / 33% | 5.2% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.2% / 33% | 9.4% / 33% | 0.5% / 33% | N/A | ✓ HALAL |
| FTSE | 11.5% / 33% | 88.9% / 33% | 5.2% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 94.1% | |
| Operating Margin | -18.6% | |
| Net Margin | -30.1% | |
| Return on Equity (ROE) | -42.5% | |
| Return on Assets (ROA) | -16.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$190M |
| Free Cash Flow | -$193M |
| Total Debt | $348M |
| Debt-to-Equity | 57.7 |
| Current Ratio | 4.0 |
| Total Assets | $1.3B |
Price & Trading
| Last Close | $518.76 |
| 50-Day MA | $464.66 |
| 200-Day MA | $442.24 |
| Avg Volume | 345K |
| Beta | -1.0 |
|
52-Week Range
$265.00
| |
About MADRIGAL PHARMACEUTICALS, INC. (MDGL)
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MADRIGAL PHARMACEUTICALS, INC. (MDGL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MADRIGAL PHARMACEUTICALS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MADRIGAL PHARMACEUTICALS, INC.'s debt ratio?
MADRIGAL PHARMACEUTICALS, INC.'s debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.5%.
What are MADRIGAL PHARMACEUTICALS, INC.'s key financial metrics?
MADRIGAL PHARMACEUTICALS, INC. has a market capitalization of $11.7B, and revenue of $958M. The company maintains a gross margin of 94.1% and a net margin of -30.1%. Return on equity stands at -42.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.